Investors Re-evaluate Kidney Disease as New Cell and Gene Therapy Strategies Emerge

In a recent episode of BioSpace's Denatured podcast, the CEOs of ProKidney and Nephrogen discussed why kidney disease has long been a difficult indication for cell and gene-based medicines.

The conversation highlighted emerging delivery platforms and novel therapeutic modalities that could overcome past technical hurdles and reach renal tissue more effectively.

Both guests pointed to clearer regulatory guidance as a key factor that may enable commercial-grade products to move forward more predictably.

As a result, investors are beginning to reassess the market potential of renal therapies, seeing renewed opportunity for growth in this historically underserved area.